Teriparatide vs Vosoritide

Evidence-based comparison. Updated 2026.

Teriparatide and vosoritide target different bone disorders through distinct mechanisms. Teriparatide is a PTH analog used for osteoporosis and fracture healing by stimulating osteoblast activity and increasing bone mineral density. Vosoritide is a CNP analog FDA-approved specifically for achondroplasia in pediatric patients, promoting endochondral bone growth at the growth plate. Neither is a substitute for the other — the correct choice depends entirely on the underlying condition.

Side by side

	Teriparatide	Vosoritide
Evidence		AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved
Regulatory		FDA approvedFDA approvedApproved by the US Food and Drug Administration for at least one use
Benefits	Increases bone mineral density Accelerates fracture healing and callus formation Reduces vertebral fracture risk Stimulates new bone formation Improves bone microarchitecture	Increases growth velocity in achondroplasia Promotes endochondral bone formation Enhances cartilage development Reduces disproportionate short stature Improves long-bone growth rate
Dosage	20 mcg, 1x daily	15 mcg, 1x daily
Route	Subcutaneous	Subcutaneous
Category	Bone & Joint Health	Bone & Joint Health

Full research page

Teriparatide

Full research page

Vosoritide

Which should you choose

Teriparatide acts on osteoblasts via PTH1 receptors to drive bone formation in mature skeletal tissue, while vosoritide acts on growth plate chondrocytes via NPR-B to promote linear bone elongation in a condition defined by impaired endochondral ossification. These are mechanistically non-overlapping peptides addressing separate physiological targets.

Choose Teriparatide when

Research or clinical context involves osteoporosis, low bone mineral density, or high vertebral fracture risk in adults
The goal is to accelerate fracture healing or callus formation following orthopedic injury
The target is osteoblast stimulation and net bone formation in cortical or trabecular bone

Choose Vosoritide when

The patient is a pediatric individual with a confirmed diagnosis of achondroplasia requiring growth intervention
The therapeutic goal is restoring endochondral ossification and increasing annualized growth velocity at the growth plate
A peptide with Grade A evidence and FDA approval specifically for its indicated condition is required

Combining teriparatide and vosoritide is not a documented or clinically relevant practice, as they address entirely different patient populations, skeletal targets, and disease mechanisms with no established rationale for concurrent use.

Questions people ask

Can teriparatide or vosoritide be used interchangeably for bone growth disorders?

No. Teriparatide promotes bone mass and remodeling in mature skeletal tissue by activating osteoblasts, making it relevant for osteoporosis and fracture healing in adults. Vosoritide specifically targets growth plate chondrocyte dysfunction in achondroplasia, a condition caused by constitutive FGFR3 activation. These peptides act on different cell types, different receptors, and are indicated for distinct, non-overlapping conditions.

How do the timelines for measurable effects compare between teriparatide and vosoritide?

Teriparatide typically shows measurable increases in bone mineral density over 6 to 18 months of daily injection, with fracture risk reduction demonstrated in longer trials. Vosoritide's effects on growth velocity are evaluated on an annualized basis, with clinical trials showing statistically significant improvements in growth rate within the first year of treatment. Both require sustained daily subcutaneous dosing to maintain effect.

Which peptide has stronger clinical evidence supporting its use?

Vosoritide holds a Grade A evidence rating and full FDA approval for achondroplasia in pediatric patients, supported by randomized controlled trial data. Teriparatide's evidence grade is listed as unknown in the research context described here, though it carries FDA approval for osteoporosis in clinical settings. For research purposes, vosoritide's evidence base for its specific indication is more clearly defined.

Is there any scenario where both teriparatide and vosoritide would be relevant to the same subject?

This would be an extremely rare and speculative scenario. Adults with achondroplasia can develop skeletal complications including abnormal bone density over time, which might theoretically raise questions about PTH-based interventions. However, no clinical protocol or published research currently supports concurrent use of both peptides, and their primary indications address different life stages and skeletal compartments.

Not sure which fits your research goals?

Use the goal finder

Answer three questions and get a peptide recommendation ranked by evidence grade.

Find my peptide